In:
Cancer, Wiley, Vol. 126, No. 2 ( 2020-01-15), p. 363-372
Abstract:
This multicenter phase 2 trial is focused on hepatic toxicity and esophagogastroendoscopy‐based gastroduodenal toxicity after stereotactic body radiotherapy in patients with hepatocellular carcinoma. On the basis of a low severe toxicity rate of 3% at 1 year, stereotactic body radiotherapy can be safely applied for the treatment of unresectable hepatocellular carcinoma in a hepatitis B virus‐endemic area.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Bookmarklink